2024 Fiscal Year Final Research Report
An exploratory study of extracellular mitochondrial proteins as novel markers of insulin resistance.
| Project/Area Number |
22K07403
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52010:General internal medicine-related
|
|---|
| Research Institution | Health Sciences University of Hokkaido |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
木村 敦 北海道大学, 理学研究院, 教授 (90422005)
大村 一将 北海道医療大学, 歯学部, 准教授 (10803637)
|
|---|
| Project Period (FY) |
2022-04-01 – 2025-03-31
|
| Keywords | インスリン抵抗性 / 病態マーカー / ミトコンドリア / タンパク質 |
|---|
| Outline of Final Research Achievements |
There is a close relationship between glucose metabolism and mitochondrial function. Therefore, this study was initiated to establish a new, mitochondria-related humoral marker that is useful for evaluating insulin resistance. To investigate the effects of imeglimin, a diabetes drug that improves insulin resistance while affecting mitochondrial function, several mitochondria-associated proteins that are secreted in response to improved skeletal muscle glucose metabolism were identified. Additionally, imeglimin was found to act on adipocytes and promote the secretion of mitokines. These proteins and mitokines may be candidates for pathological markers useful in personalized diabetes medicine.
|
| Free Research Field |
代謝病学、臨床検査医学、細胞生物学、内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究により、骨格筋由来のミトコンドリア関連タンパク質や脂肪細胞由来のマイトカインが糖尿病の病態マーカーの候補となりえることを示すことができた。個々の分子の明確な意義付けには至らなかったが、糖尿病患者の病態に即した個別化医療の推進に寄与する体液マーカーの創出において、本研究はその基盤を構築するものと考える。また、副次的に糖尿病治療薬イメグリミンの新たな作用メカニズムを解明でき、糖尿病治療おいて基礎的な視点からの病態理解に貢献することもできた。
|
